Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Current Deferred Revenue: 2019-2025

Historic Current Deferred Revenue for C4 Therapeutics (CCCC) over the last 5 years, with Sep 2025 value amounting to $37.0 million.

  • C4 Therapeutics' Current Deferred Revenue fell 25.10% to $37.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $37.0 million, marking a year-over-year decrease of 25.10%. This contributed to the annual value of $47.2 million for FY2024, which is 26.51% up from last year.
  • Per C4 Therapeutics' latest filing, its Current Deferred Revenue stood at $37.0 million for Q3 2025, which was down 15.44% from $43.8 million recorded in Q2 2025.
  • In the past 5 years, C4 Therapeutics' Current Deferred Revenue ranged from a high of $56.2 million in Q4 2021 and a low of $26.6 million during Q1 2021.
  • For the 3-year period, C4 Therapeutics' Current Deferred Revenue averaged around $42.6 million, with its median value being $43.8 million (2025).
  • Per our database at Business Quant, C4 Therapeutics' Current Deferred Revenue soared by 103.49% in 2021 and then plummeted by 40.33% in 2022.
  • C4 Therapeutics' Current Deferred Revenue (Quarterly) stood at $56.2 million in 2021, then slumped by 40.33% to $33.5 million in 2022, then increased by 11.26% to $37.3 million in 2023, then increased by 26.51% to $47.2 million in 2024, then dropped by 25.10% to $37.0 million in 2025.
  • Its Current Deferred Revenue was $37.0 million in Q3 2025, compared to $43.8 million in Q2 2025 and $46.7 million in Q1 2025.